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PUMA: A Puzzle Piece in
Chloroquine’s Antimelanoma Activity
Ravi K. Amaravadi1
Chloroquine (CQ) can induce cell death in a subset of cancer cell lines, and some
melanoma cell lines are quite susceptible. Although it is well known that CQ
impairs lysosomal function and can serve as an autophagy inhibitor, the molecular
target of CQ and the subsequent cascade of events that lead to cell death are not
fully understood. Recent evidence indicates that in melanoma cell lines, CQ
induces apoptosis by preventing degradation of the pro-apoptotic BH3-only
protein p53-upregulated modulator of apoptosis. This finding adds to the
unfolding story of CQ’s mechanism of action as a cancer therapeutic agent.
Journal of Investigative Dermatology (2013) 133, 2133–2135. doi:10.1038/jid.2013.135
Although there is clear evidence that
chloroquine (CQ) derivatives at micro-
molar concentrations impair lysosomal
function, block autophagy, and elicit
cell death in certain cancer cells, the
molecular target of CQ derivatives and
the molecular mechanism of CQ-asso-
ciated cell death have not been fully
identified. In this issue, Lakhter et al.
2013 demonstrate a critical role for the
pro-apoptotic BH3-only protein p53-
upregulated modulator of apoptosis
(PUMA) in CQ-associated cell death in
melanoma cells (Lakhter et al., 2013).
This paper provides a provocative step
forward in connecting the dots between
CQ and apoptosis that may have sig-
nificant implications for the develop-
ment of CQ derivatives to treat
melanoma and other cancers.
A brief history of CQ’s use in human
disease
CQ is one of the most widely used and
successful human drugs in the history of
medicine. Since it was first synthesized
in 1934 and its implementation as the
first effective malaria prophylactic in
1947, it is estimated that hundreds of
millions of humans have benefited from
CQ and its derivatives (Jensen and
Mehlhorn, 2009). Once widespread
resistance emerged in malaria strains,
CQ and its better tolerated derivative
hydroxychloroquine (HCQ) were reposi-
tioned to treat rheumatic diseases (Katz
and Russell, 2011). HCQ has been
tested in clinical trials as an anti-
coagulant because of its functional
effects on platelet aggregation(Carter
and Eban, 1974), as an antiviral against
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HIV (Paton et al., 2012), and as an
immunosuppressant for graft-versus-host
disease (Khoury et al., 2003). With the
exception of malaria and rheumatic
disorders, where low doses of HCQ
provide clinical benefit, randomized
trials proved that a standard dose of
HCQ provided no benefit as an anti-
coagulant, antiviral, or immunosuppres-
sive agent, despite strong preclinical
data supporting its utility for these
indications. Possible explanations for
the lack of efficacy in late-stage trials
include the lack of a dose escalation
component to earlier phase studies and
lack of mechanism-based pharmaco-
dynamic end points that would deter-
mine whether the relevant molecular
targets had been affected.
More recently, higher doses of CQ
derivatives have been tested as antic-
ancer agents. Initial studies in cancer
capitalized on the knowledge that CQ
derivatives accumulate within and
impair lysosomal function, likely block-
ing multiple cellular processes, includ-
ing autophagy. Autophagy is a multistep
catabolic process that consists of
sequestration of damaged organelles
and proteins in autophagic vesicles,
followed by fusion with lysosomes,
leading to the degradation of autophagic
vesicle contents and recycling of sugars,
amino acids, and lipids. Although it is
clear that autophagy has pro-death and
pro-survival roles in different contexts,
there is increasing evidence that in
advanced cancer, autophagy improves
the fitness of cancer cells, as it serves
to rid the struggling cancer cells of
damaged organelles, recycle basic
building blocks, and provide an internal
source of energy. There is some evi-
dence that basal levels of autophagy are
increased in solid tumors (Lazova et al.,
2012), as they cope with the metabolic
stress of limited resources within the
tumor microenvironment and unbridled
growth fueled by oncogenes. Certain
cancers such as melanoma can have
very high levels of autophagy (Lazova
et al., 2012). Melanoma may be intrin-
sically prone to high autophagy levels,
as much of the machinery involved
in melanogenesis are components of
autophagy, rendering most melano-
cytes professionally autophagic. Cancer
therapies induce autophagy, further
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providing a rationale for combining
anticancer agents with autophagy inhi-
bitors (Amaravadi et al., 2011). There-
fore, substantial effort has been devoted
to developing strategies to therapeu-
tically target autophagy in cancer cells.
However, to date, the CQ derivatives
CQ and HCQ, and a novel dimeric CQ
Lys05 (McAfee et al., 2012) are the only
pharmacological compounds known
to modulate autophagy and elicit cell
death in animal models, and therefore
they are the only clinically viable auto-
phagy inhibitors. Clinical trials of com-
binations involving HCQ are underway,
and one of the most striking findings
has been early signs of unique activity
in patients with advanced melanoma
compared with other solid tumors
when treated with the mTOR inhibitor
temsirolimus and HCQ (Amaravadi
et al., 2011). This initial activity, and
the activity demonstrated in numerous
preclinical studies, has renewed interest
in understanding CQ’s mechanism of
antimelanoma activity.
CQ’s mechanism of action
At concentrations greater than 10mM,
numerous extralysosomal candidate tar-
gets for CQ, which may or may not be
related to autophagy, have been
reported. These include DNA, glycogen
synthase kinase 3 beta (Taha et al.,
2008), NADH quinone oxidoreductase 2
(Graves et al., 2002), aldehyde
dehydrogenase 1 (Graves et al., 2002),
and chemokine receptor 4 (Kim et al.,
2012). Therefore, similar to most drugs
that have utility in medicine, CQ may
have multiple molecular targets and
therefore multiple mechanisms of action,
all of which may be dose-dependent.
Human pharmacokinetic studies con-
ducted in patients with rheumatoid
arthritis (Munster et al., 2002) and preli-
minary data from HCQ trials in cancer
patients have demonstrated that low
micromolar concentrations of HCQ
(o10mM) are achieved with the highest
clinically tolerable doses of HCQ. At
these concentrations, HCQ may not
bind sufficiently to modulate the targets
mentioned, but as there is abundant
evidence that CQ derivatives accumu-
late within the lysosomes (McAfee et al.,
2012), there is a possibility that auto-
phagy will be blocked to some extent at
clinically tolerated doses.
Putting aside the possibility of a dose-
dependent molecular target, it is clear
that a subset of human cancer cell lines
undergo cell death in vitro when treated
with single-agent CQ derivatives. The
mechanism of cell death that follows
CQ treatment is another ‘‘black box’’.
It is clear that CQ treatment of cancer
cells can block autophagy, producing a
burst of reactive oxygen species, fol-
lowed by DNA damage and activation
of DNA damage response–induced
apoptosis. Studies have implicated mul-
tiple redox-dependent genes as having
roles in the fate of CQ-treated cells (Bray
et al., 2012). Although these studies
have established a potential cascade of
events through multiple genes that may
have roles in cell death, the molecular
underpinnings of CQ-induced cell death
are still not clear.
Enhancing PUMA’s ability to kill
In this issue, Lakhter et al. (2013) report
the effects of high-dose CQ (50mM) on a
panel of melanoma and non-melanoma
cells. The investigators find that specific
melanoma cell lines undergo CQ-
induced apoptosis much more readily
than normal cells or a sampling of
colon, lung, or breast cancer cell lines.
CQ was found to stabilize PUMA levels
post-translationally, and CQ-associated
PUMA stabilization requires an intact
BH3 domain. Other lysosomal auto-
phagy inhibitors did not stabilize
PUMA to the extent that CQ did.
Finally, knockdown of PUMA-abrogated
CQ-associated cytotoxicity implicates
PUMA stabilization as at least one
important part of CQ’s antitumor
mechanism of action.
This work raises a number of ques-
tions: how is PUMA, a protein typically
bound to the mitochondria, modulated
by CQ, a compound that accumulates
significantly in lysosomes? Could this be
a lysosome-independent effect of CQ?
Could it be owing to binding and
inhibition of some of the other targets
mentioned above, which are all
extralysosomal? While included in the
study by Lakhter et al. (2013), other
inhibitors of lysosomal or autophagic
function, including bafilomycin, lyso-
somal protease inhibitors, and a pro-
ximal inhibitor of autophagy, did not
stabilize PUMA levels; CQ-induced
PUMA stabilization could still be
primarily a secondary consequence of
lysosomal inhibition. For example, CQ
may somehow be more effective than
lysosomal deacidification with bafilo-
mycin or lysosomal protease inhibition
by blocking autophagic vesicle–
lysosome fusion, (somehow) leading to
the stabilization of PUMA. It is unclear
whether other pro-apoptotic BH3-only
proteins, such as NOXA, are also
stabilized by CQ. Future studies will
focus on identifying the protein com-
plexes responsible for BH3 domain-
dependent PUMA degradation and
whether CQ binds to these proteins.
Finally, additional studies are needed
to determine whether lower concentra-
tions of CQ, such as those achieved in
preclinical models and human trials,
can also induce a PUMA-dependent
cell death.
Nevertheless, this study is important
because it shows a clear effect of CQ
on PUMA protein degradation, a novel
Clinical Implications
 Chloroquine (CQ) derivatives have been used to treat a number of
diseases, but a dose-dependent mechanism of action may explain why
they are effective for some disorders and not for others.
 A subset of melanoma cell lines undergo cell death in response to CQ, but
the molecular target and mechanism of action of CQ-induced cell death
are still not fully understood.
 PUMA-dependent cell death following CQ treatment could provide a
rationale for selecting patients for CQ-based therapies based on PUMA
expression and following the effectiveness of novel CQ derivatives
designed for cancer therapy by measuring PUMA modulation in tumors.
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mechanism of action of CQ in human
cancer cell lines in which PUMA is not
chromosomally deleted and p53-depen-
dent induction of PUMA is intact. If this
mechanism is confirmed, measurement
of PUMA expression before treatment
could identify patients who might be
susceptible to CQ-based therapies, and
serial measurement of PUMA in tumor
tissue could serve as a biomarker of CQ
efficacy. Further dissection of the mole-
cular mechanism by which CQ stabi-
lizes PUMA could yield new targets for
other therapeutics. As more and more
evidence supports the testing of lysoso-
mal autophagy inhibitors in cancer, the
puzzling pieces of CQ’s mechanism of
action should be put together, hopefully
avoiding the fate that CQ derivatives
had in other diseases.
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Skin-Specific Drug Delivery: A Rapid
Solution to Skin Diseases?
Christian D. Sadik1 and Detlef Zillikens1
In this issue of the Journal of Investigative Dermatology, Kouno et al. achieve skin-
specific drug delivery using an antibody to deliver substances in a highly specific
manner to nontransformed cells. They make use of a nonpathogenic anti-
desmoglein 3 autoantibody that had been derived from a patient with pemphigus
vulgaris to deliver drugs to the surface of keratinocytes. This approach may turn
out to be a new ‘‘magic bullet’’, thereby revolutionizing the therapy of skin
disease. The authors then used a conjugate of this antibody with a new drug
entity, TNF-related apoptosis-inducing ligand, to demonstrate, as a proof of
principle, that their approach has the potential to facilitate the treatment of both
cancerous and inflammatory skin diseases.
Journal of Investigative Dermatology (2013) 133, 2135–2137. doi:10.1038/jid.2013.231
Systemic immunosuppression—an
avoidable risk?
Autoimmune diseases constitute a com-
plex and diverse array of diseases, fea-
turing either systemic or organ-specific
inflammation. The latter is more com-
mon and is sometimes restricted to skin.
However, therapeutic strategies in both
systemic and organ-specific autoim-
mune diseases usually include the use
of systemic immunosuppressive drugs.
Systemic immunosuppression bears
numerous unwanted consequences for
patients, including increased risk of
infection and malignancy. Furthermore,
the drugs that are used may also be
associated with other severe side effects,
including diabetes, hypertension, and
pneumonitis. With regard to these pos-
sible sequelae of systemic immunosup-
pression on one the hand and the organ
restriction of inflammation on the other,
the obvious question is how to circum-
vent these disadvantages of systemic
immunosuppression. Tissue-specific
drug delivery, restraining immunosup-
pression to disease-affected tissues,
may be the ‘‘magic bullet’’ that solves
this concern.
Tissue-specific drug delivery
Tissue-specific drug delivery aims at
increasing the concentration of a drug
in a specific target tissue compared with
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